Cargando…

Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: implications for treatment and discovery of potential therapeutic signatures

BACKGROUND: Receptor tyrosine kinase (RTK) inhibitors are frequently used to treat cancers and the results have been mixed, some of these small molecule drugs are highly successful while others show a more modest response. A high number of studies have been conducted to investigate the signaling mec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jian, Halfter, Kathrin, Zhang, Mengying, Saad, Christian, Xu, Kai, Bauer, Bernhard, Huang, Yijiang, Shi, Lei, Mansmann, Ulrich R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580552/ https://www.ncbi.nlm.nih.gov/pubmed/31208363 http://dx.doi.org/10.1186/s12885-019-5804-0

Ejemplares similares

Computational modeling of methionine cycle-based metabolism and DNA methylation and the implications for anti-cancer drug response prediction
por: Zhang, Mengying, et al.
Publicado: (2018)

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
por: Quintanal-Villalonga, A., et al.
Publicado: (2016)

Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
por: Apsel, Beth, et al.
Publicado: (2008)

AutoAnalyze in Systems Biology
por: Saad, Christian, et al.
Publicado: (2019)

Corrigendum to “Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications”
por: Quintanal-Villalonga, A., et al.
Publicado: (2018)

Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition
por: Couëtoux du Tertre, Mathilde, et al.
Publicado: (2020)

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer
por: Dervisis, Nikolaos, et al.
Publicado: (2016)

Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges
por: Butti, Ramesh, et al.
Publicado: (2018)

Computational discovery and experimental verification of tyrosine kinase inhibitor pazopanib for the reversal of memory and cognitive deficits in rat model neurodegeneration
por: Yang, Yongliang, et al.
Publicado: (2015)

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor
por: Kim, Hyung-Gu, et al.
Publicado: (2013)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
por: Iyer, Sudarshan R, et al.
Publicado: (2023)

Bioactive Phytoconstituents as Potent Inhibitors of Tyrosine-Protein Kinase Yes (YES1): Implications in Anticancer Therapeutics
por: Yang, Chunmin, et al.
Publicado: (2022)

Inhibition of Bruton’s Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer’s Disease
por: Keaney, James, et al.
Publicado: (2019)

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
por: Nikolopoulos, Dionysis, et al.
Publicado: (2023)

Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma
por: Crose, Lisa E. S., et al.
Publicado: (2011)

Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor
por: Kim, Hyung-Gu, et al.
Publicado: (2014)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
por: Hempel, Cornelius, et al.
Publicado: (2017)

Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents
por: Wang, Jinfeng, et al.
Publicado: (2017)

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties
por: Wang, Xiaojing, et al.
Publicado: (2017)

Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity
por: Cho, Hyewon, et al.
Publicado: (2020)

Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton’s Tyrosine Kinase Inhibitor
por: Lee, Keun Woo, et al.
Publicado: (2020)

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
por: Allert, Catana, et al.
Publicado: (2022)

The Discovery of a Reciprocal Relationship between Tyrosine-Kinase Signaling and Cullin Neddylation
por: Friend, Samantha F., et al.
Publicado: (2013)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib
por: Kim, T-M, et al.
Publicado: (2011)

Discovering gene expression signatures responding to tyrosine kinase inhibitor treatment in chronic myeloid leukemia
por: Cha, Kihoon, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
por: Lorenzo-Vizcaya, Ana, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
por: Verougstraete, Nick, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer
por: Puisset, Florent, et al.
Publicado: (2023)

Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD
por: Lee, Hyun-ju, et al.
Publicado: (2023)

Therapeutic effects of axitinib, an anti-angiogenic tyrosine kinase inhibitor, on interstitial cystitis
por: Shin, Jung Hyun, et al.
Publicado: (2023)

Implications of the Receptor Tyrosine Kinase Axl in Gastric Cancer Progression
por: He, Lirui, et al.
Publicado: (2020)

Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton’s Tyrosine Kinase
por: Lee, Eun, et al.
Publicado: (2020)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto, Ross A, et al.
Publicado: (2015)

Prohibitin: a potential therapeutic target in tyrosine kinase signaling
por: Ande, Sudharsana Rao, et al.
Publicado: (2017)

Tyrosine Kinase Targeting: A Potential Therapeutic Strategy for Diabetes
por: Althubiti, Mohammad
Publicado: (2022)

Therapeutic Potential of Protein Tyrosine Kinase 6 in Colorectal Cancer
por: Jerin, Samanta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fp0qprcfndsokp17g1ope38o8t